Press Releases

Email Alerts

Mar 21, 2019

Biostage to Host Conference Call to Discuss 2018 Financial Results and Business Update

- Conference Call with Live Audio Webcast on Thursday March 28th at 9:00 AM ET -

Biostage, Inc. (OTCQB: BSTG), a biotechnology company developing bioengineered organ implants to treat life-threatening conditions of the esophagus, bronchus and trachea, announced today that it...
Jan 28, 2019

First-In-Human Case Using Biostage's Bioengineered Esophageal Implant is Presented at Major Surgical Meeting

Dennis Wigle, M.D., Ph.D, chair of thoracic surgery at Mayo Clinic in Rochester, Minnesota, speaking at the Society of Thoracic Surgeons Tech-Con 2019 meeting on January 26, announced for the...
Nov 8, 2018

Mr. Matthew Dallas and Mr. Jeffrey Young Appointed to Biostage Board of Directors

Biostage, Inc. (OTCQB: BSTG), a biotechnology company developing bioengineered organ implants to treat life-threatening conditions of the esophagus, bronchus and trachea, today announced that Mr....
- Photos 1
Nov 8, 2018

Biostage Reports 2018 Third Quarter Financial Results

- Scientific feedback along with new and consistent data continue to validate technology

Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a biotechnology company developing bioengineered organ implants to treat life-threatening conditions of the esophagus, bronchus and...
Nov 7, 2018

Ms. Ting Li Appointed to Biostage Board of Directors

Biostage, Inc. (OTCQB: BSTG), a biotechnology company developing bioengineered organ implants to treat life-threatening conditions of the esophagus, bronchus, and trachea, today announced...
- Photos 1
Nov 6, 2018

Biostage awarded $1.1 million Phase II NIH SBIR Fast-Track grant to develop Cellspan™ Esophageal Implant (CEI) as a novel treatment for pediatric esophageal atresia

- These nondilutive funds support development, testing and IND submission of the Company's pediatric esophageal implant candidate

Biostage, Inc. (OTCQB: BSTG), a biotechnology company developing bioengineered organ implants to treat life-threatening conditions of the esophagus, bronchus and trachea, today announced it has...
Nov 2, 2018

Biostage to Host Conference Call to Discuss Third Quarter 2018 Financial Results and Operations

- Conference Call with Live Audio Webcast on Thursday November 8th at 9:30 AM ET -

Biostage, Inc. (OTCQB: BSTG), a biotechnology company developing bioengineered organ implants to treat life-threatening conditions of the esophagus, bronchus and trachea, announced today that it...
Aug 14, 2018

Biostage Reports 2018 Second Quarter Financial Results

- Company making steady progress on mid-term goals

Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a biotechnology company developing bioengineered organ implants to treat life-threatening conditions of the esophagus, bronchus and...
Aug 9, 2018

Biostage to Host Conference Call to Discuss Second Quarter 2018 Financial Results and Operations

- Conference Call with Live Audio Webcast on Tuesday, August 14th at 9:00 AM ET -

Biostage, Inc. (OTCQB: BSTG), a biotechnology company developing bioengineered organ implants to treat life-threatening conditions of the esophagus, bronchus and trachea, announced today that it...
May 31, 2018

Biostage Closes $3.6 Million Private Placement at a price of $3.60 per share

Biostage, Inc. (OTCQB: BSTG), a biotechnology company developing bioengineered organ implants to treat life-threatening conditions of the esophagus, bronchus and trachea, today announced that the...
May 31, 2018

Hong Yu Appointed President of Biostage

Biostage, Inc. (OTCQB: BSTG), a biotechnology company developing bioengineered organ implants to treat life-threatening conditions of the esophagus, bronchus and trachea, has elected Hong Yu as...
May 25, 2018

Dr. Wei Zhang Elected to Biostage's Board of Directors

Biostage, Inc. (OTCQB: BSTG), a biotechnology company developing bioengineered organ implants to treat life-threatening conditions of the esophagus, bronchus and trachea, today announced that Dr....
- Photos 1
May 10, 2018

Biostage Reports 2018 First Quarter Financial Results

- Steady progress in the new year signals strengthening financial and technology positions

Biostage, Inc. (OTCQB: BSTG), a biotechnology company developing bioengineered organ implants to treat life-threatening conditions of the esophagus, bronchus and trachea, today announced its...
May 4, 2018

Biostage to Host Conference Call to Discuss First Quarter 2018 Financial Results and Operations

- Conference Call with Live Audio Webcast on Thursday, May 10th at 9:00 AM ET -

Biostage, Inc. (OTCQB: BSTG), a biotechnology company developing bioengineered organ implants to treat life-threatening conditions of the esophagus, bronchus and trachea, announced today that it...
Apr 2, 2018

Biostage Reports 2017 Financial Results

- Fourth Quarter Headcount Reduction and Private Placement Extend Operational Runway

Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a biotechnology company developing bioengineered organ implants to treat life-threatening conditions of the esophagus, bronchus and...
- Photos 1
Mar 29, 2018

Biostage Names Distinguished Children's Hospital Executive James Shmerling to its Board of Directors

Biostage, Inc. (OTCQB: BSTG), a biotechnology company developing bioengineered organ implants to treat life-threatening conditions of the esophagus, bronchus and trachea, today announced that it...
- Photos 1
Mar 29, 2018

Biostage awarded SBIR Fast-Track grant to develop Cellspan™ Esophageal Implant (CEI) as a novel treatment for esophageal atresia in pediatric patients

- Potential to provide up to $1.7 million of nondilutive funds to support pre-clinical testing of Company's pediatric esophageal implant product candidate

Biostage, Inc. (OTCQB: BSTG), a biotechnology company developing bioengineered organ implants to treat life-threatening conditions of the esophagus, bronchus and trachea, today announced it has...
Mar 13, 2018

Biostage Preclinical Study Results Published in New Report

Large-animal study results published in Nature Scientific Reports show successful esophageal regeneration

Biostage, Inc. (OTCQB: BSTG), a biotechnology company developing bioengineered organ implants to treat conditions of the esophagus, bronchus and trachea, today announced the publication of...
Feb 20, 2018

Biostage Closes $1 Million Private Placement

Biostage, Inc. (OTCQB: BSTG), a biotechnology company developing bioengineered organ implants to treat conditions of the esophagus, bronchus and trachea, today announced the previously disclosed...
Feb 12, 2018

Biostage Appoints to its Scientific Advisory Board Charles S. Cox, Jr., MD

Biostage, Inc. (OTCQB: BSTG), a biotechnology company developing bioengineered organ implants to treat conditions of the esophagus, bronchus and trachea, today announced the appointment of Charles...
- Photos 1
Feb 7, 2018

Biostage, Inc. Names Jason Chen Chairman of its Board of Directors

Biostage, Inc. (OTCQB: BSTG), a biotechnology company developing bioengineered organ implants to treat life-threatening conditions of the esophagus, bronchus and trachea, today announced that it...
- Photos 1
Feb 6, 2018

Biostage to Host Conference Call to Provide Business Update

- Conference Call with Live Audio Webcast on Tuesday, February 13th at 9:00 AM ET -

Biostage, Inc. (OTCQB: BSTG), a biotechnology company developing bioengineered organ implants to treat life-threatening conditions of the esophagus, bronchus and trachea, today announced that on...
Jan 31, 2018

Biostage Appoints to its Scientific Advisory Board Christine Finck, MD, Executive Vice President, Surgeon-in-Chief at Connecticut Children's Medical Center

Biostage, Inc. (OTCQB: BSTG), a biotechnology company developing bioengineered organ implants to treat life-threatening conditions of the esophagus, bronchus and trachea, today announced the...
Jan 3, 2018

Biostage Closes $4.2 Million Private Placement

- Investors strongly back technology, advancement to the clinic in U.S. Market-

Biostage, Inc. (OTCQB: BSTG/BSTGD), ("Biostage" or the "Company"), a biotechnology company developing bioengineered organ implants to treat cancers and other life-threatening conditions of the...
Dec 22, 2017

Biostage Announces Reverse Stock Split Effective December 22, 2017

- Required for financing agreement -

Biostage, Inc. (OTCQB: BSTG), ("Biostage" or the "Company"), a biotechnology company developing bioengineered organ implants to treat cancers and other life-threatening conditions of the...

Show per page